Emcure Pharmaceuticals reports Q1 FY26 consolidated PAT higher at Rs. 206.95 Cr

Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025

Emcure Pharmaceuticals, Sanofi India ink distribution agreement to broaden reach of Sanofi's oral anti-diabetic drugs

Briefs: Emcure Pharmaceuticals and Gland Pharma

Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility

Emcure Pharmaceuticals inaugurates R&D centre in Ahmedabad

The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations

Emcure Pharma’s SAKHI - Diabetes awareness program makes to Asia Book of Records

Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness

Emcure and Dhoni, through a video, urge everyone to be aware about symptoms of stroke and educate at least one person for identification of stroke and spread its awareness

Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr

Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024

Emcure Pharma forms subsidiary to strengthen dermatology portfolio

The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings

Emcure Pharmaceuticals launches solution for menopause wellness ‘Arth’ in India

Effective, holistic, science-backed targeted solutions for symptomatic treatment

Emcure Pharmaceuticals signs PPA with Sunsure Energy for solar power

The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants